| IRESS Limited (IRE) ORDINARY FULLY PAID |
Information Technology |
$1,091 |
Response to media speculation
|
8 Aug 2025 9:21AM |
$8.380 |
$5.840 |
fallen by
30.31%
|
|
IRE - Price-sensitive ASX Announcement
Full Release
Key Points
- IRESS Limited addressed media speculation on acquisition interest
- Engagement with Blackstone for a previous A$10.50 per share offer
- Current discussions with Blackstone and Thoma Bravo are exploratory
- No certainty of a forthcoming or binding offer
- Shareholders advised not to take action
- Commitment to maximizing shareholder value
- 2025 half-year financial results to be released on 11 August 2025
- Advisors are King & Wood Mallesons and Goldman Sachs
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$9 |
Change in substantial holding
|
8 Aug 2025 9:20AM |
$0.086 |
$0.023 |
fallen by
73.26%
|
|
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$9 |
Change in substantial holding
|
8 Aug 2025 9:20AM |
$0.086 |
$0.023 |
fallen by
73.26%
|
|
| TMK Energy Limited (TMK) ORDINARY FULLY PAID |
Energy |
$39 |
LF-07 INTERSECTS 54 METRES OF NET COAL
|
8 Aug 2025 9:17AM |
$0.002 |
$0.145 |
risen by
7,150%
|
|
TMK - Price-sensitive ASX Announcement
Full Release
Key Points
- LF-07 well successfully drilled and logged at the Gurvantes XXXV Coal Seam Gas Project.
- Well intersected 54 metres of net coal thickness.
- Coal seams correlate with those discovered in previous wells.
- Continuity of coal distribution across the pilot area is confirmed.
- Completion and stimulation of LF-07 well are planned.
- Dewatering and gas production testing will follow.
- Results support the ongoing pilot production program.
- The outcome is a positive step for evaluating commerciality of the resource.
- Further updates will be provided as the pilot program advances.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,617 |
Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
|
8 Aug 2025 9:16AM |
$17.550 |
$12.790 |
fallen by
27.12%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline.
- Positive pre-clinical results with NNZ-2591 in an in-vitro model.
- SYNGAP1-related disorder involves impaired synaptic communication.
- No approved treatments currently exist for SYNGAP1-related disorder.
- Commencement of Phase 3 clinical trial for Phelan-McDermid syndrome.
- NNZ-2591 targets multiple neurodevelopmental disorders.
- Orphan drug designation in the U.S. provides development incentives.
- Neuren partners with Acadia Pharmaceuticals for trofinetide.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$9 |
Cleansing Notice
|
8 Aug 2025 9:15AM |
$0.086 |
$0.023 |
fallen by
73.26%
|
|
| Air New Zealand Limited (AIZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Industrials |
$1,067 |
Air New Zealand Investor Update (Op Stats) June 2025
|
8 Aug 2025 9:13AM |
$0.535 |
$0.330 |
fallen by
38.32%
|
|
| Greatland Resources Limited (GGP) ORDINARY FULLY PAID |
Materials |
$9,495 |
Response to ASX Aware Query
|
8 Aug 2025 9:13AM |
$5.220 |
$14.110 |
risen by
170.31%
|
|
GGP - Price-sensitive ASX Announcement
Full Release
Key Points
- Greatland Resources Limited (GGP) responded to queries from the ASX regarding a significant drop in the company's share price following the release of their June 2025 Quarterly Report.
- The company explained that the Updated Production Target, Updated Capital Cost Information, and Updated Operating Cost Information were disclosed at the time of the June 2025 Quarterly Report after approval from the Board.
- GGP undertook a comprehensive FY26 budgeting and planning process, which involved analyzing operational data from the Telfer operations acquired in December 2024.
- The budgeting process considered a variety of factors, including mine schedule changes and ore grade, leading to increased growth capital investment approved for FY26.
- GGP assured compliance with ASX Listing Rule 3.1 on continuous disclosure, confirming that all necessary information was disclosed appropriately.
- GGP's responses to the ASX were authorized and approved in line with their continuous disclosure policy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Greatland Resources Limited (GGP) ORDINARY FULLY PAID |
Materials |
$9,495 |
Response to ASX Aware Query
|
8 Aug 2025 9:13AM |
$5.220 |
$14.110 |
risen by
170.31%
|
|
GGP - Price-sensitive ASX Announcement
Full Release
Key Points
- Greatland Resources Limited responded to an ASX Aware Query regarding material changes in its FY26 production and capital expenditure forecasts.
- The company's FY26 gold production target was downgraded from 300-340 koz to 260-310 koz.
- The FY26 All-In Sustaining Cost (AISC) forecast was adjusted from $2,400-$2,600/oz to $2,400-$2,800/oz.
- The FY26 Telfer Growth Capital forecast was increased from $80 million to $230-$260 million.
- These changes were a result of detailed assessments and the FY26 budget process.
- The company confirmed the updated forecasts were approved post the board meeting in July 2025.
- Greatland Resources Limited emphasized compliance with ASX Listing Rules and continuous disclosure obligations.
- The update led to a significant drop in GGP's share price and increased trading volumes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strategic Energy Resources Limited (SER) ORDINARY FULLY PAID |
Materials |
$12 |
Update to Appendix 2A - 1 August 2025
|
8 Aug 2025 9:13AM |
$0.006 |
$0.220 |
risen by
3,566.67%
|
|
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$9 |
Application for quotation of securities - BTN
|
8 Aug 2025 9:12AM |
$0.086 |
$0.023 |
fallen by
73.26%
|
|
| Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$19 |
Bioshares Biotech Summit Presentation
|
8 Aug 2025 9:11AM |
$0.685 |
$0.145 |
fallen by
78.83%
|
|
| Platinum Capital Limited (PMC) ORDINARY FULLY PAID |
Financials |
- |
Weekly Net Tangible Asset Backing
|
8 Aug 2025 9:09AM |
$1.420 |
$1.765 |
risen by
24.30%
|
|
| Platinum Asia Investments Limited (PAI) ORDINARY FULLY PAID |
Financials |
- |
Weekly Net Tangible Asset Backing
|
8 Aug 2025 9:09AM |
$1.165 |
$0.970 |
fallen by
16.74%
|
|
| Washington H. Soul Pattinson and Co. Limited (SOL) ORDINARY FULLY PAID |
Financials |
$16,188 |
SOL Despatch of Notice of Meeting and Proxy Form
|
8 Aug 2025 9:07AM |
$42.160 |
$42.610 |
risen by
1.07%
|
|
| Osteopore Limited (OSX) ORDINARY FULLY PAID |
Health Care |
$4 |
Change in substantial holding
|
8 Aug 2025 9:06AM |
$0.011 |
$0.006 |
fallen by
45.45%
|
|
| Great Divide Mining Ltd (GDM) ORDINARY FULLY PAID |
Materials |
$23 |
Change of Director's Interest Notice - Adam Arkinstall
|
8 Aug 2025 9:06AM |
$0.410 |
$0.340 |
fallen by
17.07%
|
|
| Great Divide Mining Ltd (GDM) ORDINARY FULLY PAID |
Materials |
$23 |
Change of Director's Interest Notice - Paul Ryan
|
8 Aug 2025 9:05AM |
$0.410 |
$0.340 |
fallen by
17.07%
|
|
| Asian Investment Corporation Limited (ANV) ORDINARY FULLY PAID |
- |
- |
Next Interest Payment Date
|
8 Aug 2025 9:04AM |
n/a |
n/a |
n/a
|
|
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
Release of Supplementary Explanatory Memorandum
|
8 Aug 2025 9:04AM |
$0.315 |
$0.170 |
fallen by
46.03%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- BETR Entertainment Limited (BBT) issued a supplementary explanatory memorandum on 16 May 2024.
- The memorandum supplements previous disclosures about the proposed acquisition of BBT by BETR.
- It provides further clarification in response to shareholder and regulatory queries.
- Financial and strategic rationales for the acquisition are detailed.
- Implications for shareholders, including benefits and risks, are discussed.
- Updates on the regulatory approval process are provided.
- The board maintains its recommendation that shareholders vote in favor of the acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
Supplementary Explanatory Memorandum (Selective Buy-Back)
|
8 Aug 2025 9:04AM |
$0.315 |
$0.170 |
fallen by
46.03%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- The Memorandum supplements the original Explanatory Memorandum dated 22 May 2023.
- BETR Entertainment Limited (formerly BBT Entertainment Limited) proposes a Selective Buy-Back of shares.
- The document explains the rationale for the buy-back and its anticipated advantages for the company and its shareholders.
- Details of the buy-back process, including legal, financial, and regulatory aspects, are provided.
- The Memorandum outlines procedural aspects and voting requirements for shareholders at the upcoming general meeting.
- Independent expert advice is summarized regarding the fairness and reasonableness of the buy-back proposal.
- Directors offer their recommendations and disclose updates or corrections to prior disclosures.
- The document discusses the impact of the buy-back on shareholder interests, company control, and potential tax implications.
- Shareholders are encouraged to review all materials and consider seeking independent advice before voting.
- The Supplementary Memorandum aims to ensure full transparency and inform shareholder decision-making ahead of the buy-back resolution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brickworks Limited (BKW) ORDINARY FULLY PAID |
Materials |
- |
BKW - Despatch of Notice of Meeting and proxy form
|
8 Aug 2025 9:03AM |
$34.500 |
$33.020 |
fallen by
4.29%
|
|
| COSOL Limited (COS) ORDINARY FULLY PAID |
Information Technology |
$40 |
FY25 Full Year Results Investor Call Details
|
8 Aug 2025 9:03AM |
$0.585 |
$0.220 |
fallen by
62.39%
|
|
| Osteopore Limited (OSX) ORDINARY FULLY PAID |
Health Care |
$4 |
OSX & Universiti Malaya initiate dental bone healing trial
|
8 Aug 2025 9:00AM |
$0.011 |
$0.006 |
fallen by
45.45%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,406 |
Approval to Escalate Dosing in Kidney Disease Clinical Trial
|
8 Aug 2025 8:59AM |
$1.245 |
$1.430 |
risen by
14.86%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC Therapeutics Limited has received approval from the Data Safety Monitoring Board (DSMB) to escalate dosing in its Phase 1 clinical trial for patients with autosomal dominant polycystic kidney disease (ADPKD).
- The DSMB approval follows the successful completion of the initial single ascending dose cohort in the trial, with no safety concerns observed.
- The first-in-human trial evaluates PYC’s lead investigational drug, PYC001, intended to treat ADPKD, a chronic kidney disorder with significant unmet medical need.
- The trial's primary objective is to assess the safety, tolerability, and pharmacokinetics of PYC001 in ADPKD patients.
- The dosing escalation marks an important milestone for the clinical development of PYC001 and supports PYC’s broader pipeline strategy.
- PYC Therapeutics will continue advancing its research and development efforts with a focus on genetically defined kidney diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
